Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Batten Disease: early-phase trial registry

5 of 12 indexed Batten Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 5 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Batten Disease: 12 US clinical trials tracked, 5 recruiting.

Batten Disease is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Emily de los Reyes, running 2 of these trials.

Enrollment posture brief

Registry condition batten-disease

OPEN 5 | RECR 42% | LATE 0 | EARLY 5 | RANK #1429 | SPON 2

Nearest open-share peer: Adiposity (42% recruiting · 12 trials)

Batten Disease (this)42%Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Batten Disease

Batten Disease lists 5 open slots (42% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Batten Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Batten Disease is recruiting below its size-band peers.

    5 of 12 indexed trials (41.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Batten Disease research.

    Emily de los Reyes accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical Batten Disease enrolment sits around 48 participants.

    Median target enrolment is 48 among the 12 trials that report a genuine target (sentinel values excluded). 7 of those (58.3%) plan for fewer than 100 participants.

  4. Batten Disease splits between interventional and observational designs.

    5 interventional and 7 observational studies make up this index (41.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 22

Open and recent trials

12 total, page 1 of 1

RECRUITING 20,000 participants

Inherited Retinal Degenerative Disease Registry

Foundation Fighting Blindness

NCT02435940

RECRUITING 10,000 participants

NYSCF Scientific Discovery Biobank

New York Stem Cell Foundation Research Institute

NCT06203106

RECRUITING 500 participants

Clinical and Neuropsychological Investigations in Batten Disease

University of Rochester

NCT01873924

RECRUITING 300 participants

Investigations of Juvenile Neuronal Ceroid Lipofuscinosis

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NCT03307304

RECRUITING Phase 1 40 participants

UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells

Joanne Kurtzberg, MD

NCT02254863

ACTIVE NOT RECRUITING 30 participants

Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 Diseae

Emily de los Reyes

NCT03285425

ACTIVE NOT RECRUITING 10 participants

Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene Transfer

Emily de los Reyes

NCT04273243

ACTIVE NOT RECRUITING Phase 1 7 participants

Gene Therapy for Children With CLN3 Batten Disease

Alcyone Therapeutics

NCT03770572

COMPLETED Phase 2 135 participants

Stem Cell Transplant for Inborn Errors of Metabolism

Masonic Cancer Center, University of Minnesota

NCT00176904

COMPLETED 48 participants

Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis

Weill Medical College of Cornell University

NCT01035424

COMPLETED Phase 1 43 participants

Human Placental-Derived Stem Cell Transplantation

New York Medical College

NCT01586455

COMPLETED Phase 2 14 participants

A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease

BioMarin Pharmaceutical

NCT02678689

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2

Named interventions

Most-linked intervention names on Batten Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Intracerebroventricular access device Device
1 trials
BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1) Biological
1 trials
Busulfan, Cyclophosphamide, Antithymocyte Globulin Drug
1 trials
Human Placental Derived Stem Cell Drug
1 trials
High dose CLN-301 Genetic
1 trials
Low dose CLN-301 Genetic
1 trials
Natural history Other
1 trials
AT-GTX-501 Genetic
1 trials

US sites by state

Facility locations filed on Batten Disease trials. A trial with sites in several states counts in each.

Ohio 4 trials
New York 4 trials
Maryland 2 trials
Utah 1 trials
North Carolina 1 trials
Minnesota 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Batten Disease page

12 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Batten Disease condition card totals 12 registered trials; most-linked intervention Intracerebroventricular access device; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.